- Curriculum vitae ITA: Scarica allegato
- Curriculum vitae ENG: Download
- Citation Index: 2326
- H-Index & Publication (Scopus): https://www.scopus.com/authid/detail.uri?authorId=7003610466
- ORCID (Id): http://orcid.org/0000-0002-8351-5952
Dr. Tesei’s work has focused on the search for innovative anti-cancer therapeutic approaches in the fields of pharmacology and radiobiology, and she has developed preclinical models closely mimicking in vivo tumor conditions. She has also researched into cancer stem cell isolation, stem cell self-renewal and stemness maintenance. She has long-standing research experience in the following areas: mechanisms of action of antineoplastic drugs, hormone therapy, targeted therapy and drug combinations, radio-and drug-sensitivity and resistance pathways, DNA repair mechanisms, 3D cell cultures. Within the context of a multidisciplinary research collaboration with the Institute of Organic Chemistry and Photoreactivity (Italian National Reserach Council, CNR), Dr. Tesei is a co-inventor of two USA-granted patents pertaining to synthesis methodology of novel SARMs that are effective against castrate-resistant prostate cancer models. She is the author and co-author of several scientific articles published in peer-reviewed national and international scientific journals, and of numerous Abstracts presented at international conferences. As head of a research team, she is frequently involved in student mentoring activities and acts as thesis co-advisor for undergraduates and PhD and Masters students.
Head of Drug Discovery and Radiobiology Unit at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l. IRCCS, Meldola (FC), Italy.
1993: graduated in Biological Science at the University of Bologna.
1998: Specialized in Biochemistry and Clinical Chemistry at the Medicine Faculty of the University of Parma
2006: PhD in Pharmacology and Toxicology at the University of Bologna
2011-2015: CNR associated researcher at ISOF-CNR Institute of Bologna
US 20120041046 A1: Non-steroidal compounds for androgen receptor modulation
US 20110275829 A1: Androgen receptor modulating compounds, preparation and uses thereof
Reviewer for Scientific Reports, Clinical Cancer Research, Computer Methods and Programs in Biomedicine, Cellular Physiology, British Journal of Pharmacology, Advanced Biosystems and other journals.
Review Editor for Frontiers in Endocrinology and Frontiers in Oncology
Editorial Board Member of Current Pharmaceutical Biotechnology